NCT00622336 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 70 months
What was measured
Duration of response based on the Myeloma response determination criteria developed by Bladé et al 1998 and defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on International Myeloma Working Group (IMWG) criteria.
Analysis population: Duration of response not analyzed per the sponsors decision.
Groups in this outcome
Lenalidomide 25mg
Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle
| Group | Source count |
|---|---|
| Lenalidomide 25mg | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Duration of response based on the Myeloma response determination criteria developed by Bladé et al 1998 and defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on International Myeloma Working Group (IMWG) criteria.
- groups
- description
- Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle
- id
- OG000
- title
- Lenalidomide 25mg
- population Description
- Duration of response not analyzed per the sponsors decision.
- reporting Status
- POSTED
- time Frame
- Up to 70 months
- title
- Duration of Response
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle